Indolent Systemic Mastocytosis Clinical Trial
Official title:
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04910685 -
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
|
Phase 2/Phase 3 | |
| Completed |
NCT03632811 -
Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language
|
||
| Completed |
NCT02808793 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
|
Phase 1 | |
| Completed |
NCT02478957 -
Treatment of Indolent Systemic Mastocytosis With PA101
|
Phase 2 | |
| Completed |
NCT03770273 -
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
|
Phase 2 | |
| Recruiting |
NCT04333108 -
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
|
Phase 3 | |
| Not yet recruiting |
NCT06210698 -
Angioedema Biomarker Research Study
|
||
| Completed |
NCT00814073 -
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
|
Phase 3 | |
| Active, not recruiting |
NCT01920204 -
Midostaurin in Indolent Systemic Mastocytosis
|
Phase 2 |